Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis
CELL PROLIFERATION
Authors: Liu, Yu; Qi, Jian; Dou, Zhen; Hu, Jiliang; Lu, Li; Dai, Haiming; Wang, Hongzhi; Yang, Wulin
Abstract
Objectives Many cancer cells depend on G2 checkpoint mechanism regulated by WEE family kinases to maintain genomic integrity. The PKMYT1 gene, as a member of WEE family kinases, participates in G2 checkpoint surveillance and probably links with tumorigenesis, but its role in breast cancer remains largely unclear. Materials and Methods In this study, we used a set of bioinformatic tools to jointly analyse the expression of WEE family kinases and investigate the prognostic value of PKMYT1 in breast cancer. Results The results indicated that PKMYT1 is the only frequently overexpressed member of WEE family kinases in breast cancer. KM plotter data suggests that abnormally high expression of PKMYT1 predicts poor prognosis, especially for some subtypes, such as luminal A/B and triple-negative (TNBC) types. Moreover, the up-regulation of PKMYT1 was associated with HER2-positive (HER2+), basal-like (Basal-like), TNBC statuses and increased classifications of Scarff, Bloom and Richardson (SBR). Co-expression analysis showed PKMYT1 has a strong positive correlation with Polo-like kinase 1 (PLK1), implying they may cooperate in regulating cancer cell proliferation by synchronizing rapid cell cycle with high quality of genome maintenance. Conclusions Collectively, this study demonstrates that overexpression of PKMYT1 is always found in breast cancer and predicts unfavourable prognosis, implicating it as an appealing therapeutic target for breast carcinoma.
Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells
INTERNATIONAL JOURNAL OF ONCOLOGY
Authors: Jiang, Jiahua; Sliva, Daniel
Abstract
Mushrooms are an integral part of Traditional Chinese Medicine (TCM), and have been used for millennia to prevent or treat a variety of diseases Currently mushrooms or their extracts are used globally in the form of dietary supplements In the present study we have evaluated the anticancer effects of the dietary supplement MycoPhyto (R) Complex (MC), a novel medicinal mushroom blend which consists of a blend of mushroom mycelia from the species Agaricus blazei, Cordyceps sinensis, Coriolus verstcolor, Ganoderma lucidum, Grifola frondosa and Polyporus umbellatus, and beta-1,3-glucan isolated from the yeast, Saccharomyces cerevisiae Here, we show that MC demonstrates cytostatic effects through the inhibition of cell proliferation and cell cycle arrest at the G2/M phase of highly invasive human breast cancer cells MDA-MB-231 DNA-microarray analysis revealed that MC inhibits expression of cell cycle regulatory genes (ANAPC2, ANAPC2 BIRC5, Cyclin B1 Cychn H, CDC20 CDK2, CKS1B Cullin 1 E2F1 KPNA2 PKMYT1 and TFDP1) Moreover, MC also suppresses the metastatic behavior of MDA-MB-231 by the inhibition of cell adhesion, cell migration and cell invasion The potency of MC to inhibit invasiveness of breast cancer cells is linked to the suppression of secretion of the urokinase plasminogen activator (uPA) from MDA-MB-231 cells In conclusion, the MC dietary supplement could have potential therapeutic value in the treatment of invasive human breast cancer